Absence of a telomere maintenance mechanism as a favorable prognostic factor in patients with osteosarcoma

Gary A. Ulaner, Hsuan Ying Huang, Jesse Otero, Zhiquan Zhao, Leah Ben-Porat, Jaya M. Satagopan, Richard Gorlick, Paul Meyers, John H. Healey, Andrew G. Huvos, Andrew R. Hoffman, Marc Ladanyi

Research output: Contribution to journalArticle

142 Citations (Scopus)

Abstract

There are two telomere maintenance mechanisms (TMMs) in human tumors, telomerase activation (TA) and, more rarely, the process termed alternative lengthening of telomeres (ALT). Unlike most carcinomas, sarcomas, including osteosarcomas (OS), have been reported to display TA and ALT in more balanced proportions and, thus, present an opportunity to examine the impact of different TMMs on clinical tumor behavior. We studied OS samples from 62 patients for molecular evidence of TA and ALT. Kaplan-Meier analysis demonstrated that the absence of both TA and ALT (in 18%) was more strongly associated with improved survival (P = 0.05) than were stage (P = 0.16) or chemotherapy response (P = 0.18) in this group of patients with OS. Subsets of OS cases with either TA or ALT did not differ significantly from each other in clinical outcome. There were no significant associations of presence, absence, or type of TMM with patient age, stage, or chemotherapy response. Thus, the absence of a detectable TMM may identify a favorable clinical subset of OS patients. Our study also suggests that the likelihood of detecting correlations between TMMs and clinical outcome in studies of certain other tumor types might be improved if, in addition to TA, ALT is included in future analyses. Finally, we note that OS cases with a TA-/ ALT+ phenotype seem to be as clinically aggressive as TA+ cases in terms of stage and clinical outcome.

Original languageEnglish (US)
Pages (from-to)1759-1763
Number of pages5
JournalCancer Research
Volume63
Issue number8
StatePublished - Apr 15 2003
Externally publishedYes

Fingerprint

Telomere Homeostasis
Telomerase
Telomere
Osteosarcoma
Maintenance
Drug Therapy
Neoplasms
Kaplan-Meier Estimate
Sarcoma
Outcome Assessment (Health Care)
Carcinoma
Phenotype
Survival

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Ulaner, G. A., Huang, H. Y., Otero, J., Zhao, Z., Ben-Porat, L., Satagopan, J. M., ... Ladanyi, M. (2003). Absence of a telomere maintenance mechanism as a favorable prognostic factor in patients with osteosarcoma. Cancer Research, 63(8), 1759-1763.

Absence of a telomere maintenance mechanism as a favorable prognostic factor in patients with osteosarcoma. / Ulaner, Gary A.; Huang, Hsuan Ying; Otero, Jesse; Zhao, Zhiquan; Ben-Porat, Leah; Satagopan, Jaya M.; Gorlick, Richard; Meyers, Paul; Healey, John H.; Huvos, Andrew G.; Hoffman, Andrew R.; Ladanyi, Marc.

In: Cancer Research, Vol. 63, No. 8, 15.04.2003, p. 1759-1763.

Research output: Contribution to journalArticle

Ulaner, GA, Huang, HY, Otero, J, Zhao, Z, Ben-Porat, L, Satagopan, JM, Gorlick, R, Meyers, P, Healey, JH, Huvos, AG, Hoffman, AR & Ladanyi, M 2003, 'Absence of a telomere maintenance mechanism as a favorable prognostic factor in patients with osteosarcoma', Cancer Research, vol. 63, no. 8, pp. 1759-1763.
Ulaner GA, Huang HY, Otero J, Zhao Z, Ben-Porat L, Satagopan JM et al. Absence of a telomere maintenance mechanism as a favorable prognostic factor in patients with osteosarcoma. Cancer Research. 2003 Apr 15;63(8):1759-1763.
Ulaner, Gary A. ; Huang, Hsuan Ying ; Otero, Jesse ; Zhao, Zhiquan ; Ben-Porat, Leah ; Satagopan, Jaya M. ; Gorlick, Richard ; Meyers, Paul ; Healey, John H. ; Huvos, Andrew G. ; Hoffman, Andrew R. ; Ladanyi, Marc. / Absence of a telomere maintenance mechanism as a favorable prognostic factor in patients with osteosarcoma. In: Cancer Research. 2003 ; Vol. 63, No. 8. pp. 1759-1763.
@article{1cb6b862f22443b992fc208891dac1f8,
title = "Absence of a telomere maintenance mechanism as a favorable prognostic factor in patients with osteosarcoma",
abstract = "There are two telomere maintenance mechanisms (TMMs) in human tumors, telomerase activation (TA) and, more rarely, the process termed alternative lengthening of telomeres (ALT). Unlike most carcinomas, sarcomas, including osteosarcomas (OS), have been reported to display TA and ALT in more balanced proportions and, thus, present an opportunity to examine the impact of different TMMs on clinical tumor behavior. We studied OS samples from 62 patients for molecular evidence of TA and ALT. Kaplan-Meier analysis demonstrated that the absence of both TA and ALT (in 18{\%}) was more strongly associated with improved survival (P = 0.05) than were stage (P = 0.16) or chemotherapy response (P = 0.18) in this group of patients with OS. Subsets of OS cases with either TA or ALT did not differ significantly from each other in clinical outcome. There were no significant associations of presence, absence, or type of TMM with patient age, stage, or chemotherapy response. Thus, the absence of a detectable TMM may identify a favorable clinical subset of OS patients. Our study also suggests that the likelihood of detecting correlations between TMMs and clinical outcome in studies of certain other tumor types might be improved if, in addition to TA, ALT is included in future analyses. Finally, we note that OS cases with a TA-/ ALT+ phenotype seem to be as clinically aggressive as TA+ cases in terms of stage and clinical outcome.",
author = "Ulaner, {Gary A.} and Huang, {Hsuan Ying} and Jesse Otero and Zhiquan Zhao and Leah Ben-Porat and Satagopan, {Jaya M.} and Richard Gorlick and Paul Meyers and Healey, {John H.} and Huvos, {Andrew G.} and Hoffman, {Andrew R.} and Marc Ladanyi",
year = "2003",
month = "4",
day = "15",
language = "English (US)",
volume = "63",
pages = "1759--1763",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "8",

}

TY - JOUR

T1 - Absence of a telomere maintenance mechanism as a favorable prognostic factor in patients with osteosarcoma

AU - Ulaner, Gary A.

AU - Huang, Hsuan Ying

AU - Otero, Jesse

AU - Zhao, Zhiquan

AU - Ben-Porat, Leah

AU - Satagopan, Jaya M.

AU - Gorlick, Richard

AU - Meyers, Paul

AU - Healey, John H.

AU - Huvos, Andrew G.

AU - Hoffman, Andrew R.

AU - Ladanyi, Marc

PY - 2003/4/15

Y1 - 2003/4/15

N2 - There are two telomere maintenance mechanisms (TMMs) in human tumors, telomerase activation (TA) and, more rarely, the process termed alternative lengthening of telomeres (ALT). Unlike most carcinomas, sarcomas, including osteosarcomas (OS), have been reported to display TA and ALT in more balanced proportions and, thus, present an opportunity to examine the impact of different TMMs on clinical tumor behavior. We studied OS samples from 62 patients for molecular evidence of TA and ALT. Kaplan-Meier analysis demonstrated that the absence of both TA and ALT (in 18%) was more strongly associated with improved survival (P = 0.05) than were stage (P = 0.16) or chemotherapy response (P = 0.18) in this group of patients with OS. Subsets of OS cases with either TA or ALT did not differ significantly from each other in clinical outcome. There were no significant associations of presence, absence, or type of TMM with patient age, stage, or chemotherapy response. Thus, the absence of a detectable TMM may identify a favorable clinical subset of OS patients. Our study also suggests that the likelihood of detecting correlations between TMMs and clinical outcome in studies of certain other tumor types might be improved if, in addition to TA, ALT is included in future analyses. Finally, we note that OS cases with a TA-/ ALT+ phenotype seem to be as clinically aggressive as TA+ cases in terms of stage and clinical outcome.

AB - There are two telomere maintenance mechanisms (TMMs) in human tumors, telomerase activation (TA) and, more rarely, the process termed alternative lengthening of telomeres (ALT). Unlike most carcinomas, sarcomas, including osteosarcomas (OS), have been reported to display TA and ALT in more balanced proportions and, thus, present an opportunity to examine the impact of different TMMs on clinical tumor behavior. We studied OS samples from 62 patients for molecular evidence of TA and ALT. Kaplan-Meier analysis demonstrated that the absence of both TA and ALT (in 18%) was more strongly associated with improved survival (P = 0.05) than were stage (P = 0.16) or chemotherapy response (P = 0.18) in this group of patients with OS. Subsets of OS cases with either TA or ALT did not differ significantly from each other in clinical outcome. There were no significant associations of presence, absence, or type of TMM with patient age, stage, or chemotherapy response. Thus, the absence of a detectable TMM may identify a favorable clinical subset of OS patients. Our study also suggests that the likelihood of detecting correlations between TMMs and clinical outcome in studies of certain other tumor types might be improved if, in addition to TA, ALT is included in future analyses. Finally, we note that OS cases with a TA-/ ALT+ phenotype seem to be as clinically aggressive as TA+ cases in terms of stage and clinical outcome.

UR - http://www.scopus.com/inward/record.url?scp=0344837710&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0344837710&partnerID=8YFLogxK

M3 - Article

C2 - 12702558

AN - SCOPUS:0344837710

VL - 63

SP - 1759

EP - 1763

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 8

ER -